Sacubitril-valsartan: Hope or hype in the battle against cardiotoxicity due to cancer treatment?

Kardiol Pol. 2022;80(9):958-959. doi: 10.33963/KP.a2022.0166. Epub 2022 Jul 14.

Authors

Kenan Yalta¹, Murat Gok², Cihan Ozturk², Tulin Yalta³

Affiliations

¹ Department of Cardiology, Trakya University, Erdine, Turkey. [email protected].
² Department of Cardiology, Trakya University, Erdine, Turkey.
³ Department of Pathology, Trakya University, Edirne, Turkey.

PMID: 35833474
DOI: 10.33963/KP.a2022.0166

No abstract available

MeSH terms

Aminobutyrates / adverse effects
Angiotensin Receptor Antagonists / adverse effects
Biphenyl Compounds
Cardiotoxicity / etiology
Drug Combinations
Heart Failure* / chemically induced
Heart Failure* / drug therapy
Humans
Neoplasms* / drug therapy
Stroke Volume
Tetrazoles / adverse effects
Valsartan / therapeutic use

Substances

Aminobutyrates
Angiotensin Receptor Antagonists
Biphenyl Compounds
Drug Combinations
Tetrazoles
sacubitril
Valsartan